Optimal dose of hepatobiliary contrast agent for MR cholangiography: Experimental study in rats

Journal of Magnetic Resonance Imaging

Volumn 8, Issue 4, 1998, Pages 847-852

  Hirohashi, Shinji ^a   Hirohashi, Rina ^a   Uchida, Hideo ^a   Kitano, Satoru ^a   Akira, Megumi ^a   Ono, Wataru ^a   Ohishi, Hajime ^a   Kato, Naoki ^b   Takahashi, Masaya ^b   Miyazawa, Tomoaki ^b  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Research Department   (Japan)

Author keywords

Hepatobiliary contrast agent; Liver; MR cholangiography; MRI

Indexed keywords

CONTRAST MEDIUM; GADOXETIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHOLANGIOGRAPHY; CONCENTRATION RESPONSE; CONTRAST RADIOGRAPHY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HEPATOBILIARY SYSTEM; IMAGE ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO;

ANIMALS; BILE DUCTS; CONTRAST MEDIA; GADOLINIUM DTPA; LIVER; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0031824358     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880080414     Document Type: Article

References (18)

1. Hemmingson A, Carlsten J, Ericksson A, et al. MR-cholangiography with a double contrast technique. Acta Radiol 1989; 30: 29-33.
2. Bollow M, Taupitz M, Hamm B, Stacks T, Wolf KJ, Weinmann HJ. Gadolinium-ethoxybenzyl-DTPA as a new hepatobiliary contrast medium for MR cholangiography: results of an in-vivo phase I clinical evaluation. Eur Radlol 1997; 7:126-132.
3. Lauffer RB, Greif WL, Stark DD, et al. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies. J Comput Assist Tomogr 1985; 9:431-438.
4. Lauffer RB, Vincent AC, Padmanabhan S, et al. Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives. Magn Reson Med 1987; 4:582-590.
5. Hoener B, Tzika AA, Engelstad BL, White DL. Hepatic transport of the magnetic resonance imaging contrast agent Fe(III)-N-(3-phenylglutaryl)desferroxamine B. Magn Reson Med 1991; 17: 509-515.
6. Hoener B, Engelstad BL, Ramos EC, et al. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents. J Magn Reson Imaging 1991; 1:357-362.
7. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, Raymond KN. Manganese(II) N,N′-dipyridoxylenediamtne-N,N′-diacetate 5,5′-bis(phosphate): synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 1989; 28:477-485.
8. Elizondo G, Frez C, Stark DD, et al. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991; 178:73-78.
9. Hamm B, Vogl TJ, Branding G, et al. Focal liver lesions: MR imaging with Mn-DPDP: initial clinical results in 40 patients. Radiology 1992; 182:167-174.
10. Vittadini G, Felder E, Tirone P, Lorusso V. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988; 23(Suppl 1):S246-S248.
11. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 1990; 176: 61-64.
12. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium menzyloxy-propionictetra-acetate (BOPTA): preliminary results of phase II clinical application. Radiology 1996; 199:513-520.
13. Weinmann H, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22:233-237.
14. Schuhmann-Giampieri G, Schmitt-Willich H, Press W, Negishi C, Weinmann H, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183:59-64.
15. Ni Y, Marchai G, Lukito G, Yu J, Mühler A, Baert AL. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 1994; 190:753-758.
16. Hamm B, Stacks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195:785-792.
17. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200:59-67.
18. Reinhold C, Bret PM. Current status of MR cholangiopancreatography. AJR Am J Roentgenol 1996; 166:1285-1295.